Antipsychotic-induced hyperprolactinemia in Tourette syndrome

• Published in: Therapeutic Advances in Psychopharmacology 2017-07, Vol.7 (6-7), p.201-205
• Main Authors: Rath, Judith J. G., Deen, Marlies E. J., van Houten, Hessel, de Bruijn, Sebastiaan F. T. M., van Gerven, Joop, Mul, Dick
• Format: Article
• Language: English
• Subjects: Antidepressants; Antipsychotics; Psychotropic drugs; Review; Tourette syndrome
• ISSN: 2045-1253; 2045-1261
• DOI: 10.1177/2045125317705012

For many years, Tourette syndrome (TS) was considered to be a rare disorder, but tics and TS are now recognized as fairly common childhood-onset conditions. Children and adolescents with TS are frequently treated with antipsychotics, either as monotherapy or in combination with psychostimulants, melatonin and selective serotonin reuptake inhibitors (SSRIs). Antipsychotics are most often used in schizophrenia and related psychotic disorders, and in these conditions hyperprolactinemia is one of the most common adverse effects associated with antipsychotics, occurring in 40–50% of patients. We describe two patients with TS who experienced antipsychotic-induced hyperprolactinemia. Treatment options generally consist of dose reduction or switching from typical to atypical antipsychotics. However, diminishing dosages can lead to exacerbations of tics. Also, not all atypical antipsychotics have the same pharmacologic properties required to normalize prolactin levels. The choice of treatment may also be affected by the patient’s age and sex. These factors are discussed in relation to these cases, and illustrated by the results of therapeutic interventions over the years.